Board Member
Oruka Therapeutics, Inc. (ORKA)Board Member
Jade Biosciences, Inc. (JBIO)Equibles does not estimate personal net worth.
Get an email with a short summary when Oruka Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ORKA alertsLawrence Klein is recorded as CEO and Board Member at Oruka Therapeutics, Inc. (ORKA) and Board Member at Jade Biosciences, Inc. (JBIO) since January 1, 2025. The newest filing on record that lists Lawrence Klein as CEO and Board Member at Oruka Therapeutics, Inc. (ORKA) is dated April 17, 2026. The newest filing on record that lists Lawrence Klein as Board Member at Jade Biosciences, Inc. (JBIO) is dated April 28, 2026. Jade Biosciences, Inc. reported in an 8-K filed May 1, 2025 that Lawrence Klein was appointed Board of Directors, effective April 28, 2025. Oruka Therapeutics, Inc. reported in an 8-K filed September 5, 2024 that Lawrence Klein was appointed director (Class II), effective August 29, 2024. Oruka Therapeutics, Inc. reported in an 8-K filed September 5, 2024 that Lawrence Klein was appointed President and Chief Executive Officer, effective August 29, 2024. The proxy statement of Oruka Therapeutics, Inc. reports total compensation of $3,356,050 for Lawrence Klein in fiscal 2025, including a base salary of $624,000. Disclosed compensation is on record for 2 fiscal years. Lawrence Klein has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Oruka Therapeutics, Inc. on June 3, 2026. Oruka Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Jade Biosciences, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Oruka Therapeutics, Inc. includes Thomas A. Keuer (CEO), Samarth Kulkarni (Chairman and Board Member), C. Jeff Dekker (CFO) and 7 others.
“On April 28, 2025, the Board decreased its size from seven to six members and appointed the following six individuals to the Board: Eric Dobmeier, Christopher Cain, Tom Frohlich, Tomas Kiselak, Lawrence Klein and Erin Lavelle.”
“On August 29, 2024, the Board increased its size from five to six members and appointed the following six individuals to the Board: Lawrence Klein, Kristine Ball, Carl Dambkowski, Peter Harwin, Samarth Kulkarni and Cameron Turtle.”
“So our goal when we set up the company a few years ago was to have potentially best-in-class assets in psoriatic disease. going after what we think are the two best targets in that indication space, IL-23 and IL-17AF, and really with a goal to sort of perfect the product profile of agents that could inhibit those…”
“Thank you all for joining us this morning as we announce interim results from Everlast A, a study of ORCA001, our extended half-life IL-23 P19 inhibitor, and moderate to severe plaque psoriasis.”
2025-01-01–present
Last confirmed April 28, 2026
Start not stated–present
Last confirmed April 17, 2026
Start not stated–present
Last confirmed April 17, 2026
Biotechnology · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Oruka Therapeutics, Inc. (ORKA) | Chief Executive Officer | $624,000 | $3,356,050 |
| 2024 | Oruka Therapeutics, Inc. (ORKA) | Chief Executive Officer | $203,288 | $520,911 |
